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Sulfation is a common modiﬁcation of extracelluar glycans and tyrosine residues on pro-
teins, which is important in many signalling pathways and interactions. Existing methods
for studying sulfotransferases, the enzymes that catalyse sulfation, are cumbersome and
low-throughput. Recent studies published in the Biochemical Journal have repurposed
established biochemical assays from the kinase ﬁeld and applied them to the character-
isation of sulfotransferases. Biochemical screening of a library of kinase inhibitors
revealed that compounds that target RAF kinases may also be repurposed to inhibit sul-
fotransferases. Together with the available structures of sulfotransferases, these studies
open the door to the development of chemical tools to probe the biological functions of
these important enzymes.
Biological sulfation (also called sulfonation) is a widespread covalent chemical modiﬁcation of biomo-
lecules by the addition of a sulfonyl group (SO3 ) [1]. Whereas protein kinases use ATP as a source of
bioavailable phosphate to phosphorylate their target proteins, inorganic sulfate is made available for
incorporation into biomolecules in the form of PAPS (30-phosphoadenosine 50-phosphosulfate)
through a process in which ATP is ﬁrst sulfated by the ATP sulfurylase enzyme to generate adenosine
50-phosphosulfate, which is then phosphorylated on the 30 position of the ribose ring to generate
PAPS. Sulfation is carried out by a class of enzymes called sulfotransferases. Two of the most
common substrates for sulfation are saccharides intended for secretion (glycan sulfation) and the side
chains of tyrosine residues on proteins (tyrosine sulfation). In humans, there are 2 tyrosyl protein sul-
fotransferases (TPST1 and TPST2), 4 heparan sulfotransferases (HS2ST1, HS6ST1, HS6ST2 and
HS6ST3) and 15 other carbohydrate sulfotransferases (CSHT1–15). These proteins are localised to the
Golgi apparatus and function in the post-translational modiﬁcation of proteins destined for the outer
membrane or extracellular secretion. Regulated sulfation plays a vital role in many extracellular inter-
actions and signalling pathways.
Protein tyrosine sulfation was ﬁrst described in bovine ﬁbrinogen in 1954 [2]. It has been estimated
that 7% of mammalian proteins are sulfated on tyrosine residues, although the functional conse-
quences of these post-translational modiﬁcations have been deﬁned in only a few cases [3]. Many che-
mokine receptors are tyrosine sulfated in their N-terminal regions [4]. This was ﬁrst described in
CCR5, a co-receptor for HIV entry through recognition of CD4, and is critical for recognition by the
HIV-1 gp120 protein [5]. Sulfation also contributes to the binding of chemokine ligands, such as
CCL3 and CCL4. The interactions between other chemokine receptors and their native or pathogenic
ligands are also enhanced by sulfation [4]. Antibodies can also be sulfated on tyrosine residues, thus
increasing the repertoire of the surface that recognises antigens through a mechanism that mimics the
post-translational modiﬁcation of co-receptors [6].
Of the ﬁve major classes of glycosaminoglycans, hyaluronan lacks sulfate groups, while the other
four are sulfated: heparan, chondroitin, dermatan and keratan [7]. Sulfated glycans fulﬁl important
biological functions in the extracellular matrix and on the surfaces of cells, providing structural
strength and mediating signalling via speciﬁc binding interactions, and therefore the process of
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sulfation is carefully regulated within the Golgi network. For example, variations in the sulfation patterns of
heparan sulfate inﬂuence the binding of chemokines and growth factors. Misregulation of glycan sulfation (for
instance due to genetic disorders) is associated with a range of developmental syndromes, inﬂammation, infec-
tion and other medical conditions. For instance, a subset of HS6ST1 mutations that are implicated in idiopathic
hypogonadotrophic hypogonadism (IHH), a genetic disease characterised by delayed onset of puberty, map to
the catalytic domain of the enzyme and may contribute to the recognition of glycan substrate [8].
To date, unlike the well-developed protein kinase ﬁeld, methods for quantifying carbohydrate and protein
sulfation are low-throughput and there are few chemical tool compounds available, hindering enzymatic
analysis and inhibitor studies. In a pair of groundbreaking back-to-back studies published in a recent issue of
the Biochemical Journal, Byrne et al. have implemented two biochemical assays to measure the binding of
ligands to the glycan sulfotransferase HS2ST1 (heparan sulfate 2-O-sulfotransferase) and protein sulfotrans-
ferases TPST1/2 (tyrosylprotein sulfotransferases 1 and 2) [9,10]. The assays used are standard in the protein
kinase ﬁeld and in these studies have been ingeniously adapted to apply to sulfation reactions. Differential scan-
ning ﬂuorimetry (DSF) and mobility shift assay (MSA) are medium-throughput assays that enable the screen-
ing of hundreds, sometimes up to thousands, of different conditions. DSF, often called thermal shift, uses the
increase in ﬂuorescence of a hydrophobic dye such as SYPRO-Orange upon binding to exposed hydrophobic
core residues to quantify the thermal denaturation of a protein under varying conditions, for instance changes
in buffer conditions or upon the binding of ligand molecules. The microﬂuidics-based MSA used by Byrne
et al. utilises novel synthetic ﬂuorescent substrates — ﬂuorescein-tagged hexasaccharide glycans or
FAM-labelled peptides derived from physiological target proteins — to carry out real-time analysis of the
enzyme kinetics of HS2ST and TPST 1/2, respectively.
These methods allow the identiﬁcation of factors that affect enzyme activity — for example, the activity of
HS2ST is stimulated by Mg2+ concentrations greater than 1 mM, whereas TPST1/2 were stabilised by cofactors
such as CoA. It would be interesting to compare the efﬁciency with which different substrates are sulfated and
to extend the study to the analysis of other sulfotransferases. Here, Byrne et al. used these assays in combin-
ation to screen the Published Kinase Inhibitor Set (PKIS) of 367 well-characterised kinase inhibitors against
TPST1 and HS2ST. Interestingly, the ‘hit rates’ against the two enzymes were markedly different: screening at
40 mM inhibitor concentration, only three compounds inhibited HS2ST activity by greater than 50%, while
more than 30 of the compounds inhibited TPST1 to a similar extent. Furthermore, all three of the top hits
against HS2ST were oxindole-derived RAF kinase inhibitors that were among the top 10 hits against TPST1. In
addition, rottlerin, a natural product that has activity against a broad set of biological targets including kinases,
was found to inhibit both TPST1 and HS2ST.
Crystal structures of sulfotransferases include the human TPST1 in complex with adenosine 30–50 diphos-
phate (PAP) and two different substrate peptides (PDB codes 5WRI and 5WRJ); and structures of chicken
HS2ST (PDB code 4NDZ) or zebraﬁsh 6-O-sulfotransferase (6-OST) (PDB codes: 5T03, 5T05 and 5T0A) in
complex with PAP and oligosaccharides [8,11,12]. The catalytic domain of sulfotransferases is unrelated to that
of protein kinases, and moreover, the way in which the substrates are held are different. Protein kinases have a
deep cleft into which ATP binds and the protein substrate binds to the surface proximal to this cleft; ATP is
held in an orientation that buries the adenine base. In contrast, the active site of sulfotransferase comprises a
tunnel with the binding sites for PAPS and peptide/glycan substrate is at either end; PAPS binds to the active
site of sulfotransferases in an orientation that exposes the adenine base to solvent. The availability of these
structures enables the binding sites of inhibitors to be predicted using computational approaches. Whereas the
kinase inhibitors compete with ATP binding to RAF, docking analysis carried out by Byrne et al. suggests that
these compounds do not have an equivalent mode of action in sulfotransferases: they do not simply compete
with the substrate molecule PAPS. Instead, some of the compounds are predicted to bind across the peptide/
glycan and PAPS-binding sites. Intriguingly, rotterlin is predicted to dock to the PAPS-binding site of HS2ST
and the peptide-binding site of TPST1.
These recent studies have identiﬁed several compounds that are potentially useful for studying sulfotrans-
ferases, with the caution that they are not selective and they also inhibit kinases. Because the size and shape of
the active sites are different from protein kinases, it should be possible to develop more speciﬁc and selective
chemical inhibitors of sulfotransferases. Robust assays such as DSF and MSA will facilitate the determination of
structure–activity relationships of inhibitors. The hit compounds from the PKIS library could be used as start-
ing points for further chemistry, although crystal structures of the sulfotransferases in complex with the inhibi-
tors would be helpful in conﬁrming the predicted binding modes and guiding further chemistry. In addition,
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the approaches that Byrne et al. have developed could be used to screen further libraries of compounds. This
need not be restricted to kinase inhibitors, and in silico approaches may help to narrow down the search for
new hit matter. Screening simple, low molecular mass compounds (<300 Da) called ‘fragments’ using biophys-
ical methods such as NMR spectroscopy might also be considered because this is an efﬁcient way to scan a
diverse set of molecules, with library sizes typically of 1000–2000, and can identify ‘hot-spots’ within the active
site [13]. From these weakly binding fragments, potent inhibitors can be developed, such as the clinically
approved BRAF inhibitor vemurafenib. With the right combination of approaches, and perhaps a little luck, it
seems likely that a toolkit of inhibitors to probe the biological functions of sulfotransferanses is just around the
corner.
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